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Autogenous saphenous vein is the best conduit for
infrainguinal and, especially, femoral-infrapopliteal
arterial bypass graft purposes. The previous use of
autogenous vein for coronary or peripheral bypass
graft, a history of superficial phlebitis, or poor quality
of the vein produces situations when an alternative
conduit must be used. Other sources of autogenous
vein (arm, lesser saphenous vein), synthetic prostheses
made from polytetrafluoroethylene (PTFE) or
Dacron, and biological grafts (eg, human umbilical
vein) have been used as alternatives for femoral-distal
bypass graft, but their results have been varied.
Cryopreserved saphenous vein allografts have been
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Purpose: Cryopreserved saphenous vein allografts are used for femoral-infrapopliteal
bypass graft purposes when adequate autogenous vein is unavailable. Anticoagulation,
immunosuppression therapy, or both have been suggested means for improving allograft
patency. Immunosuppression has significant cost and morbidity and has produced vari-
able results. Our successful treatment of luminal surface hypercoagulability associated
with certain endovascular procedures prompted the use of an anticoagulation protocol
prospectively to improve graft patency and limb salvage for patients receiving femoral-
infrapopliteal cryopreserved saphenous vein allografts.
Methods: Between September 1995 and October 1999, 24 patients (15 men and nine women)
were enrolled in a prospective clinical trial for salvage of 26 severely ischemic lower limbs with
femoral-infrapopliteal cryopreserved saphenous vein allograft bypass grafts. All patients were
treated with a protocol (aspirin, low-dose heparin, low molecular weight dextran 40, dipyri-
damole, and warfarin), and no immunosuppressive agents were used. The cryopreserved
saphenous vein allografts were matched to patients by ABO and Rh compatibility. Indications
for revascularization were ischemic rest pain (n = 8), nonhealing ulcer (n = 13), or focal gan-
grene (n = 5), and no usable autogenous vein was available. Follow-up ranged from 2 to 35
months (mean, 19 months). We studied the location and type of outflow anastomosis, spe-
cific outflow vessel, morbidity, death, secondary procedures (digital/transmetatarsal ampu-
tation), and complications related to the treatment protocol. Life table analyses of primary
graft patency and limb salvage were compared with other current reported data. 
Results: Primary graft patency with Kaplan-Meier life table analysis was 96% at 6 months,
87% at 12 months, and 82% at 18 and 24 months. There were no reoperations for acute
graft occlusion. One graft underwent late segmental aneurysmal degeneration and rupture.
There were no procedure-related deaths or bleeding complications. During late follow-up,
anticoagulation was discontinued in three patients (12%) because of gastrointestinal bleed-
ing. Limb salvage was 88% at 6 months and 80% at 12, 18, and 24 months. Patients
returned to ambulatory status that was limited only by their other comorbidities.
Conclusion: Femoral-infrapopliteal bypass graft for limb salvage with a cryopreserved
saphenous vein allograft can be an acceptable alternative when autogenous vein is not
available. Our treatment protocol substantially improved allograft patency and limb sal-
vage when compared with current published data. (J Vasc Surg 2000;32:731-8.)
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used for femoral-infrapopliteal bypass graft purposes
when adequate autogenous vein is unavailable.
Reported patency and limb salvage have ranged from
good to poor.1-10 The vendor for cryopreserved
greater saphenous vein allografts used in this study,
CryoLife Cardiovascular, Inc (Kennesaw, Ga), report-
ed that between June 1991 and March 1998, 286
saphenous vein allografts used for femoral-
infrapopliteal bypass grafts had a 60% primary paten-
cy at 6 months and a 36% patency at 12 months. They
also reported a corresponding limb salvage of 80% at
6 months and 69% at 1 year. The information provid-
ed by CryoLife regarding patency and limb salvage
represents a volunteer registry of the accumulated
clinical data from eight centers and 20 surgeons who
performed implants and who have been major users
of cryopreserved saphenous vein allograft. These sur-
geons’ techniques and postoperative treatment regi-
mens are delineated to a limited degree. The use of
antiplatelet therapy, anticoagulation, and methods for
determining patency is outlined in general rather than
specific terms in the CryoLife registry.
Cryopreserved saphenous vein allografts have near
ideal sewing and handling properties. They are easily
implanted without the need for harvesting or joining
autogenous vein segments and are usually readily
available, though somewhat expensive. Unfortu-
nately, cryopreserved saphenous vein allografts have
generally had poor reported patency, which has been
attributed to several causes. Carpenter and
Tomaszewski8,9 have demonstrated a sustained
immunogenic activity in cryopreserved venous allo-
grafts and suggested that the rejection response may
contribute to allograft failure. However, in the clinical
setting, they showed that the use of low-dose
immunosuppression did not substantially improve
allograft patency. Immunosuppression has significant
cost and morbidity especially for the elderly patient
with multiple comorbidities. Loss of functional
endothelial lining in cryopreserved venous allografts
has also been indicted as a cause for allograft failure.
It is estimated that cryopreservation yields approxi-
mately 50% to 80% preservation of intact endothelial
cells in venous allografts.11 These cells appear to have
decreased thrombomodulin activity and decreased
nitric oxide production with resultant impaired anti-
coagulation function.10,11 Anticoagulation has been a
suggested means for improving allograft patency. To
our knowledge, in only one previous study has a spe-
cific anticoagulation plan to alter luminal surface
hypercoagulability in venous allografts been applied.
Posner et al12 combined an anticoagulation protocol
with moderate immunosuppressive therapy and
obtained improved patency of cryopreserved venous
allografts but had substantial problems with acute
pseudoaneurysm formation and hemorrhage. They
also showed no apparent patency benefit from long-
term anticoagulation.
Previously, when we have performed procedures
that produce significant intimal denudation or
injury with potential for increased luminal surface
hypercoagulability (eg, long-segment endarterecto-
my or endovascular atherectomy), we have used an
anticoagulation protocol that was successful in pre-
venting both early and late thrombotic complica-
tions. In this study, we applied this anticoagulation
protocol prospectively in an effort to improve graft
patency and limb salvage for patients receiving
femoral-infrapopliteal cryopreserved saphenous
vein allografts.
METHODS
Between September 1995 and October 1999, 24
patients (15 men and nine women) were enrolled in
a prospective clinical trial for salvage of 26 severely
ischemic lower limbs with the use of femoral-
infrapopliteal cryopreserved saphenous vein allograft
bypass grafts. All patients were enrolled in a vascular
registry, and their accumulated clinical information
was analyzed retrospectively. The mean age was 71 ±
10 years (range, 52-89 years). Patients were selected
for the clinical trial because they had no autogenous
vein that was judged acceptable for use as a bypass
graft conduit by the operating surgeon. The greater
saphenous veins had been previously stripped or
used as arterial conduits in another location. This
included preoperative evaluation of arm and lesser
saphenous veins with duplex scan imaging technique
or direct surgical evaluation at the time of operation.
Cryopreserved saphenous vein allografts were
obtained from CryoLife Cardiovascular, Inc, and
were the only conduits used. According to the ven-
dor, veins are harvested with a “no-touch” tech-
nique and kept moist with Dulbecco modified Eagle
medium, which contains 10% bovine serum and
papaverine, 0.12 mg/mL.13 Veins were then cryo-
preserved and stored at –196°C in a mixture of
dimethyl sulfoxide and chondroitin sulfate.12,13
Surgical implantation was performed by two vascu-
lar surgeons at Scott & White Hospital, Temple,
Texas. Epidural anesthesia was used as the primary
anesthetic for the operative procedure and was also
used for postoperative pain control with continuous
infusion technique. All veins were reconstituted per
the manufacturer’s directions and averaged 3.5 to
5.5 mm in diameter. There were 19 (73%) primary
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reconstructions, 6 (23%) secondary reconstructions,
and 1 (3.9%) tertiary reconstruction. On occasion,
the length of the vein determined the location of the
proximal anastomosis. Four grafts originated from
the proximal superficial femoral artery, and one graft
was anastomosed to the deep femoral artery for
inflow. Distal anastomoses were made to the tibial
peroneal trunk in 7 patients, the peroneal artery in
11 patients, the posterior tibial artery in 7 patients,
and the anterior tibial artery in 1 patient. In no case
was more than one allograft vein used for the bypass
graft, because using joined venous allograft seg-
ments has been shown to be associated with reduced
patency.14 The allografts were matched to patients
by ABO and Rh compatibility, and all grafts were
implanted in the reversed position with fine monofil-
ament suture for construction of the anastomoses.
The type of outflow anastomosis was left to the dis-
cretion of the surgeon (eg, use of a Wolfe cuff,
Taylor patch, side-to-side arteriovenous fistula, or
direct anastomosis). 
Comorbidities of diabetes, coronary artery dis-
ease, tobacco abuse, renal insufficiency (creatinine
level > 1.5), and hypertension were prevalent.
Eighteen patients (75%) had diabetes; 10 patients
(42%) had abnormal renal function, two of whom
were undergoing hemodialysis; and 11 patients
(49%) had an extensive history of tobacco abuse. All
patients were hypertensive and had evidence of
coronary artery disease that was documented by
means of medical history, electrocardiographic find-
ings, or dipyridamole thallium studies.
Indications for revascularization were ischemic
rest pain (n = 8), nonhealing soft tissue ulceration (n
= 13), or focal gangrene (n = 5). These indications
represent grades II and III and categories 4 and 5 of
the classification for lower extremity ischemia by
The Society for Vascular Surgery and The American
Association for Vascular Surgery, a Chapter of the
International Society for Cardiovascular Surgery.15
Contrast arteriography was obtained in all
patients preoperatively and was used to identify the
best site for the distal anastomosis. In most cases,
when a tibial vessel was used for outflow, it repre-
sented the only vessel with either direct or, in the
case of the peroneal artery, indirect continuity with
a patent plantar arch.
All patients were pretreated with 162 mg of
aspirin. During the operative procedure, systemic
anticoagulation was accomplished with aqueous
heparin administered intravenously in a dose that
prolonged the activated clotting time two times the
normal rate. Heparin was not reversed at the com-
pletion of the procedure. Postoperatively, patients
received low-dose heparin infusion (aqueous heparin
at 500 U/h), which did not routinely prolong their
partial thromboplastin time. This treatment was
continued for approximately 72 hours and was
administered in conjunction with low molecular
weight dextran 40 infusion (Rheomacrodex;
Mediscan, Parsippany, NJ) at 15 to 20 mL/h, while
patients were simultaneously anticoagulated with
warfarin sodium (Coumadin; DuPont Pharma,
Wilmington, Del) to a therapeutic international nor-
malized ratio (INR) of 2.0 to 2.5. Low-dose aspirin
(81 mg/d), dipyridamole (Lederle Standard
Products, Pearl River, NY) (75 mg twice a day), and
low-dose warfarin sodium (INR 2.0-2.5) were con-
tinued indefinitely unless a clinical condition such as
gastrointestinal bleeding necessitated their discon-
tinuation. No immunosuppressive agents were used.
A first-generation cephalosporin was used to provide
perioperative antibiotic prophylaxis. 
Any required toe, partial foot, or transmetatarsal
amputations were delayed approximately 24 hours
to ensure that the revascularization procedure had
been successful. Eleven patients required some form
of toe or foot amputation.
Patient follow-up consisted of lower extremity
segmental systolic pressure measurements and seg-
mental pneumoplethysmography or pulse volume
recordings on the first visit after discharge from the
hospital, then at 6 weeks, every 3 months for 1 year,
and then at 6-month intervals. B-mode duplex ultra-
sound scan imaging of the venous allograft was per-
formed semiannually. No attempt was made to
microscopically study rejection response or changes
in allograft architecture in any of the patients. Other
authors have investigated this in detail and have
thoroughly reported their findings in previous pub-
lications.8-10,12,13
Actual charges related to the care of each patient
were obtained from hospital computerized billing
records and reported in US dollars. The costs report-
ed were related to graft placement and hospitaliza-
tion associated with that procedure. This included
most anticoagulation costs used in the perioperative
period. It did not include the costs of aspirin given to
patients after their discharge from the hospital, war-
farin, periodic patient INR surveillance, noninvasive
lower extremity vascular testing, or clinical follow-up
evaluation. Real costs in this study were based on
actual accounted-for costs, whenever possible. Some
costs covering services were derived by the use of
charge-to-cost conversion formulas that are specific
to our institution. Kaplan-Meier life table analyses of
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primary graft patency and limb salvage were com-
pared with data obtained from the registry main-
tained by CryoLife Cardiovascular, Inc.
RESULTS
Primary graft patency with Kaplan-Meier life
table analysis was 96% at 6 months, 87% at 12
months, and 82% at 18 and 24 months and was cal-
culated with the method according to Rutherford et
al15,16 (Fig 1). Data points on Fig 1 beyond 30
months represent too few patients to achieve statis-
tical significance. Patient follow-up ranged from 2 to
35 months (mean, 19 months) with a significant
number of allografts (nine of 26) available for sur-
veillance at 24 months. 
The location of inflow anastomosis, the type of
outflow anastomosis, the specific outflow artery, and
the surgeon who performed the implant had no sta-
tistically significant effect on graft patency in this
study. Twenty-one of 26 grafts originated from the
common femoral artery, and all of the grafts that
failed had inflow anastomoses to the common
femoral artery. Because 23 of 26 bypass grafts were
performed by one operating surgeon, no statistical
relevance could be related to this variable. The type
of outflow anastomosis was left to the discretion of
the operating surgeon. There were 15 unmodified
standard graft-to-target vessel anastomoses, 6 out-
flow arteriovenous fistula anastomoses, and 5 vein
patch outflow anastomoses modifications (Wolf
cuff/Taylor patch). Of the grafts that failed, one had
an outflow arteriovenous fistula, one had a vein patch
modification, and the rest had standard graft-to-tar-
get vessel anastomosis. No statistical implications
regarding the effect of the type of outflow anasto-
mosis could be made on the basis of this information. 
There were no reoperations for acute graft occlu-
sion. One graft underwent late segmental aneurys-
mal degeneration and rupture 21 months after
implant and was treated with a PTFE interposition
graft. This reconstruction continues to remain
patent. Cultures from the graft segment that was
removed were sterile and showed no evidence of
infection. Pathologic study of the surgical specimen
showed focal diffuse degeneration of graft wall lay-
ers. There were two surgical wound complications.
Skin-edge necrosis occurred in one groin and one
infrapopliteal incision and required debridement and
local wound care for healing. Two patients had
patent grafts but ultimately required below-knee
amputation because of the persistence of nonhealing
heel ulcers with local pain and sepsis that could not
be controlled. One of these patients was undergoing
long-term hemodialysis. Four of five failed grafts
resulted in proximal amputation, two above the knee
and two below the knee. The fifth failed graft
occurred 3 days before the patient’s death from car-
diac complications, and no amputation was neces-
sary. Patients who underwent amputation did so
because they declined further revascularization pro-
cedures and wanted amputation for pain control.
There were no procedure-related deaths or periop-
erative complications. During late follow-up, war-
farin anticoagulation was discontinued in three
patients (12%) because of gastrointestinal bleeding.
Limb salvage was 88% at 6 months and 80% at 12,
18, and 24 months (Fig 2). Data points on Fig 2
beyond 30 months represent too few patients to
achieve statistical significance. Patients with patent
grafts returned to an ambulatory status that was lim-
ited only by their other comorbidities.
The cost for a saphenous venous allograft is rela-
tively expensive. We spent between $4200 and
$4600 for each allograft used in this series. Total
hospital cost, reimbursement, and length of stay
were evaluated to determine whether the procedure
was cost-effective. Meaningful data could only be
obtained from computerized billing records from
patients who were operated on in 1997 through
1999 (22 patients). The average length of stay in a
hospital was 12.4 days (range, 6-30 days) in 1997;
8.2 days (range, 7-11 days) in 1998; and 6.0 days
(range, 5-7 days) in 1999. The average hospital cost
per case was $17,341 in 1997; $16,039 in 1998;
and $13,730 in 1999. The average reimbursement
(Medicare Diagnostic Related Group) was $15,997
in 1997; $14,318 in 1998; and $13,831 in 1999.
These data show minimal profit only in 1999 with
significant loss per case in other years.
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Fig 1. Primary patency of femoral-infrapopliteal CryoVein
(CryoLife) allograft bypass graft.
DISCUSSION
The availability of an off-the-shelf conduit for
femoral infrageniculate or infrapopliteal bypass graft
purposes that has the handling characteristics, com-
pliance, and durability of autogenous saphenous
vein would be near the top of a “wish list” for most
vascular surgeons. Autogenous saphenous vein is not
uniformly available when needed for distal infrain-
guinal bypass graft purposes. Synthetic prostheses of
PTFE or Dacron and biologic grafts (eg, reinforced
human umbilical vein) have been used as alternatives
to autogenous vein. Veith et al17 reported primary
patency rates of 48%, 34%, and 12% at 1, 2, and 4
years, respectively, for femoral to tibial vessel PTFE
grafts. Hobson et al18 reported 1-, 2-, and 4-year
patency rates of 21%, 18%, and 18%, respectively, for
the same procedure. Flinn et al19 reported improved
cumulative patency of 45% at 2 years when warfarin
therapy was added to femoral distal bypass grafts
with PTFE. Nevelsteen et al20 and Raithel et al21
have reported similar patency data for human umbil-
ical vein grafts used in femoral distal bypass graft
surgery. In most of these series, limb salvage exceed-
ed graft patency.
Other sources for autogenous vein (arm or less-
er saphenous vein) have had better reported patency
than synthetic conduits when used under similar cir-
cumstances.22-24 Patency rates of up to 60% at 2
years have been reported, although piecing seg-
ments of vein seem to diminish long-term patency.
In an effort to find a conduit for femoral distal
bypass graft purposes that matched many of the
characteristics of autogenous saphenous vein, the
investigation led to the use of venous allografts.
Beginning with the early work of Yamanouchi in
1911 and Carrell in 1912 and progressing to the
first clinical implantation of a saphenous vein allo-
graft as an arterial bypass graft in 1955 by Shaw and
Wheelock, we established the basis for use of venous
allografts.25,26 Further use of venous allografts iden-
tified that they were antigenic and subject to the
immunologic rejection process. Investigations by
Perloff et al,27 Williams et al,28 and Ochsner et al29
suggested that the rejection process was responsible
for allograft failure in part because of endothelial cell
destruction. Cryopreservation has been suggested as
a means of lessening immunologic response of
saphenous vein allografts.7,30-33 Additionally, 50% to
80% of allograft endothelial cells appear to remain
viable with cryopreservation though their thrombo-
modulin activity, and nitric oxide production has
been shown to be deficient.11,13 A healthy endothe-
lium is necessary for maintaining a patent conduit.
Ochsner et al29 showed increased allograft patency
in ABO-type matched fresh allografts. They hoped
that cryopreservation and ABO- and Rh-type
matching of donor graft to recipient might substan-
tially lessen the immunologic rejection response.
Carpenter and Tomaszewski8,9 have studied and
extensively reported on the immune response from
human saphenous vein allografts and suggested that
rejection was in part responsible for allograft failure.
However, they also reported that low-dose immuno-
suppression with azathioprine (Burroughs Wellcome/
Glaxo Wellcome Research, Triangle Park, NC) failed
to improve allograft patency. Posner et al12 combined
moderate immunosuppression therapy that included
methylprednisolone (Upjohn), azathioprine, and
cyclosporin A (Sandoz Pharmaceuticals, East Hanover,
NJ) in tapering doses with a postoperative anticoagu-
lation protocol consisting of therapeutic use of intra-
venous heparin, low molecular weight dextran 40,
aspirin (325 mg), therapeutic warfarin, and a vasodila-
tor, either nitroglycerin or a calcium channel blocker.
Their results showed increased cumulative primary
patency of cryopreserved venous allografts; however,
they had a substantial number of conduit-related com-
plications including early pseudoaneurysm formation
and hemorrhage. They also estimated a significant
expense (> $10,000 per year) associated with the cost
of immunosuppression therapy for patients in their
study. Finally, Lesèche et al1 reported improved cryo-
preserved venous allograft patency and limb salvage by
the use of postoperative anticoagulation with low mol-
ecular weight heparin (enoxaparin [Lovenox]; Rhone-
Poulenc Rorer, Collegeville, Pa) and aspirin therapy.
Our own experience with vascular surgical pro-
cedures that produce significant intimal injury or
intimal denudation and a subsequent potential for
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Fig 2. Limb survival after femoral-infrapopliteal CryoVein
(CryoLife) allograft bypass graft.
increased luminal surface hypercoagulability (long-
segment endarterectomy or endovascular atherecto-
my) prompted us to use a perioperative and postop-
erative anticoagulation protocol to reduce both early
and late thrombotic complications. In previous stud-
ies where cryopreserved saphenous vein allografts
were used, it has been suggested that endothelial
damage from the immune rejection response and
endothelial dysfunction from cryopreservation both
contribute to producing luminal surface hypercoag-
ulability. The anticoagulation protocol presented in
this study was used to improve venous allograft
patency by treating this potentially hypercoagulable
luminal surface.10,11,13
Our philosophy is to perform an all-autogenous
infrainguinal bypass graft procedure whenever possi-
ble. For this reason it has taken us several years to
acquire enough patients for this study. Although it is
a small series, the analysis of our results shows a very
acceptable 2-year primary patency of 82% and a 2-year
limb salvage of 80%, which compares quite favorably
with autogenous saphenous vein. No attempt was
made to study the immune rejection response in our
patients because it was beyond our capability and was
never designed as a part of the project. 
The use of cryopreserved saphenous vein allograft
has all of the same advantages of an off-the-shelf
PTFE, Dacron, or human umbilical vein conduit. It
also has the additional advantage of possessing the
handling qualities of autogenous vein. Its increased
cost requires justification for its use. With the use of
the anticoagulation protocol outlined in this article,
cryopreserved saphenous vein allograft has better
patency at 1 and 2 years than that reported for
human umbilical vein or PTFE with or without the
use of postoperative warfarin therapy.17-21 We think
this anticoagulation protocol has been responsible
for the improved patency of the saphenous vein allo-
grafts when compared with patency data provided by
the manufacturer. All of the patients in the study had
severe limb-threatening ischemia and substantial
comorbidities typical for this group of patients. The
use of an off-the-shelf conduit for limb salvage revas-
cularization reduced operating and anesthesia time.
This probably contributed to the low perioperative
morbidity and death rates. Limited incisions for con-
struction of anastomoses reduced incision-related
morbidity and often permitted early ambulation and
reduced length of hospital stay.
Analysis of length of stay, hospital costs, and
reimbursement data from 1997 through 1999 have
shown that these limb salvage revascularization pro-
cedures are frequently money-losing events for our
hospital. Despite the high cost of the cryopreserved
saphenous venous allograft, we were able to achieve
a break-even position in 1999 primarily through
judicious and appropriate use of invasive monitor-
ing, through intensive care unit resources, and
through decreased length of stay.
CONCLUSION
Femoral-infrapopliteal bypass graft with cryopre-
served saphenous vein allograft in conjunction with
our anticoagulation protocol can be an acceptable
alternative for limb salvage when autogenous vein is
unavailable. In this study, the use of a specific anti-
coagulation protocol improved allograft patency and
limb salvage when compared with other current
reported data. 
We gratefully acknowledge Mark Riggs, PhD,
Director of Biostatistics, Scott & White Hospital, who
performed the statistical analysis on the data for this study.
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DISCUSSION
Dr Linda M. Harris (Buffalo, NY). Certainly if what
he has shown here today can be duplicated with a larger
group of patients it will be a potentially very exciting
advance for vascular surgery. I do have a few criticisms and
a few questions for Dr Buckley.
The two major criticisms are ones that he has already
mentioned, which is they have a very small group of patients.
With only 24 patients it is hard to know whether or not these
results will be shown to be the same in many more patients.
Secondly, there is fairly short-term follow-up. The mean fol-
low-up was 19 months. However, the range was from 2 to
35 months. So again it may be a little bit too short and a lit-
tle too premature to make any final decisions from.
You did mention that there are multiple different types
of anastomoses used by the different surgeons. Now again
while in a small group you had similar results. I’d like to
know what number of anastomoses were Wolf, how many
were Taylor patch, how many had AV fistulas, and how
many were direct, and why these alternatives were used in
addition to a venous anastomosis. Most typically, we see
these patches with prosthetic grafts; however, you’ve cho-
sen to use them with nonprosthetic grafts. 
Secondly, in the paper three patients required discon-
tinuation of the anticoagulation secondary to bleeding.
How long were these patients followed after discontinua-
tion of the anticoagulation, and what were their out-
comes? What length of time would you recommend anti-
coagulation for, for the patients overall? In other words, if
we implant a cryopreserved vein, are we going to put them
on lifelong anticoagulation, or are we going to recom-
mend a certain period of time for anticoagulation?
Your results have shown significant improvement in
the patency of the graft versus the CryoLife data and data
from all the other reviews. However, your limb salvage was
actually lower than your patency, which is different than all
the other studies that we’ve seen out there, and I was
wondering if you could explain that. 
Lastly, the majority of yours were patients who had
primary reconstruction. These were not people who were
having secondary or tertiary procedures. Do you think it
will be different in a series where more of the bypasses are
secondary or tertiary revascularizations?
I’d like to thank the Society for the opportunity to dis-
cuss the paper.
Dr Clifford J. Buckley. Thank you Dr Harris. I’ll try
to answer these. It is a small series, first of all. In our insti-
tution, it is our policy whenever possible to do all primary
autogenous reconstruction, be it arm vein, lesser saphe-
nous, or greater saphenous, whatever happens to be avail-
able. And therefore, it took us a substantial amount of
time to find this small group of patients who had no usable
available vein for entry into this study. 
Second, the type of outflow anastomoses that was con-
structed really was left at the discretion of the implanting
surgeon. Probably the largest outflow variant was that of
creation of an outflow arteriovenous fistula and was done
in several of the patients. The exact number escapes me,
but I want to say it may have been seven or eight but sta-
tistically it had no impact on the patency data. We looked
at that specifically. Several of the vessels were what I would
consider to be heavily calcified and poor target vessels for
distal anastomoses, and therefore, a Taylor patch was used,
something to improve the diameter of the outflow anasto-
mosis. This too failed to add any statistically significant
improvement in long-term patency. We did not restrict the
outflow anastomosis to a direct anastomosis because we
really left it to the judgment of the implanting surgeon to
do whatever he thought was best based on which vessel he
was using as the target and the quality of the vessel at the
time of surgery. 
The difference between patency and limb salvage, I
think, I can explain for you. We had two patients in the
series who had large heel ulcers who underwent revascu-
larization, and they were femoral-peroneal bypass grafts.
Despite having patent reconstructions, we were unable to
affect healing of the ulcer because there were no reason-
ably good vessels going to that area, and because of
intractable pain and persistent local sepsis, these patients
went on to an amputation. Fortunately or unfortunately,
both of these CryoVein bypasses have remained patent,
and these patients continue to be followed for disease in
their other extremity, and the bypass on the amputated
extremity has continued to remain patent.
Reference your question regarding the fate of patients'
limbs whose anticoagulation was discontinued and what
recommendations we would make regarding the duration
for anticoagulation with Coumadin, I have the following
comments. We have been discontinuing dipyridamole in
most patients after 6 to 12 months of therapy. Coumadin
anticoagulation together with the administration of 81-
mg aspirin daily has generally been continued indefinitely.
Of the patients who had cessation of Coumadin therapy
because of gastrointestinal bleeding, as I mentioned, one
of them lost his limb because of graft thrombosis and
delay in return for evaluation and intervention. The other
two were actually restarted back on Coumadin anticoagu-
lation once the source of their gastrointestinal bleeding
had been identified and treated, and they continue to have
patent grafts and are back on low-dose Coumadin antico-
agulation. I think that covered everything that you asked
me, Dr Harris. If it didn’t, if I’ve left something out, let
me know.
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